AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.72 |
Market Cap | 233.49M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.85 |
PE Ratio (ttm) | -2.27 |
Forward PE | n/a |
Analyst | Buy |
Ask | 6 |
Volume | 68,830 |
Avg. Volume (20D) | 158,032 |
Open | 4.43 |
Previous Close | 4.37 |
Day's Range | 4.13 - 4.46 |
52-Week Range | 2.70 - 10.25 |
Beta | undefined |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic...
Analyst Forecast
According to 5 analyst ratings, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 209.52% from the latest price.
Next Earnings Release
Analysts project revenue of $8.14M, reflecting a 41.10% YoY growth and earnings per share of -0.27, making a -52.63% decrease YoY.